Results 41 to 50 of about 120,903,364 (211)

Immunoglobulin a nephropathy and renal transplantation

open access: yes, 1999
In this review, we discuss the incidence of immunoglobulin A (IgA) mesangial deposits and IgA mesangial nephritis recurring in renal transplants in those patients whose renal failure was caused by IgA nephropathy (IgAN) or Henoch-Schönlein purpura.
Bannister, K.   +3 more
core   +1 more source

Relapses or de-novo IgA nephropathy following COVID-19 vaccination; a narrative review [PDF]

open access: yes, 2023
Immunoglobulin A (IgA) nephropathy is the most common type of glomerulonephritis worldwide characterized by excessive serum levels of glycosylated which triggers the generation of glycan-specific IgG and IgA autoantibodies.
Shahrzad Alimohammadi   +11 more
core   +2 more sources

CASTOR1 Regulates Humoral Immune Responses and Contributes to the Pathogenesis of Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, EarlyView.
Objective CASTOR1 senses arginine and regulates mammalian target of rapamycin complex 1 (mTORC1), a central metabolic signaling molecule. This study aimed to elucidate the roles of CASTOR1 in humoral immune responses. Methods We analyzed human B cell transcriptomes from healthy controls and patients with systemic lupus erythematosus (SLE) via ...
Takeshi Kusuda   +5 more
wiley   +1 more source

Differentiation and Pathological Significance of Tissue‐Resident Memory‐Like CD8+ T Cells in Systemic Lupus Erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Tissue‐resident memory T (TRM) cells have been implicated in organ‐specific immune pathology; however, the pathological relevance of TRM‐like CD8+ T cells in systemic lupus erythematosus (SLE) remains unclear. We investigated their differentiation mechanisms and pathological significance in SLE, including associations with disease activity ...
Yuya Fujita   +10 more
wiley   +1 more source

Emerging therapies in immunoglobulin A nephropathy [PDF]

open access: yesNephrology, 2015
AbstractDespite advances in our understanding of immunoglobulin A nephropathy (IgAN) over the past decade, there are currently no specific therapies capable of targeting key pathways involved in the pathogenesis of the disease. Recent studies have, however, provided new insights into important molecular pathways that are likely to be amenable to ...
See Cheng, Yeo   +2 more
openaire   +2 more sources

Clinical, Histopathological Profile and Treatment Outcomes of Immunoglobulin A Nephropathy: A Single-center Retrospective Study from South India

open access: yesIndian Journal of Kidney Diseases
Background: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, with variable clinical presentations and outcomes.
Siddharth Herur   +8 more
doaj   +1 more source

Ceftriaxone‐associated immune haemolytic anaemia: A patient‐level systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Ceftriaxone can cause acute haemolysis. Its clinical presentation, risk factors, and outcomes remain incompletely characterized. We conducted a systematic review of published cases with patient‐level data, following international guidelines and with registration in PROSPERO (CRD420261338709). Reports were identified through three bibliographic
Sonja Miotti   +9 more
wiley   +1 more source

Hereditary Spherocytosis With Immunoglobulin A Nephropathy

open access: yes, 2010
Hereditary spherocytosis is a familial hemolytic anemia. Immunoglobulin A (IgA) nephropathy associated with hereditary spherocytosis has not been reported in children.

core   +1 more source

Unmasking of immunoglobulin a deposits posttransplant due to COVID-19 AKI-incidental or causal – A nephrologists' dilemma a case report

open access: yesIndian Journal of Transplantation, 2022
COVID-19 is a global pandemic with the chronically immunosuppressed transplant recipients being the most vulnerable both to infection as well as complications of COVID-19.
Luvdeep Dogra   +3 more
doaj   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy